Skip to main content
Division of Cancer Prevention
Division of Cancer Prevention

Search form

Main menu

  • Home
  • Major Programs
    • Cancer Prevention Fellowship Program (CPFP)
    • Early Detection Research Network (EDRN)
    • NCI Community Oncology Research Program (NCORP)
    • Alliance of Glycobiologists for Cancer Research
    • Barrett's Esophagus Translational Research Network (BETRNet)
    • Cancer Prevention Clinical Trials Network (CP-CTNet)
    • Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
    • Consortium for Imaging and Biomarkers (CIB)
    • HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network
    • Liquid Biopsy Consortium
    • Multi-Cancer Early Detection (MCED)
    • NCI Cervical Cancer ‘Last Mile’ Initiative
    • Pancreatic Cancer Detection Consortium (PCDC)
    • Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)
    • PREVENT Cancer Preclinical Drug Development Program (PREVENT)
    • Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)
    • Small Cell Lung Cancer (SCLC) Consortium
    • Supportive Care and Symptom Management
    • Translational and Basic Science Research in Early Lesions (TBEL) Program
    • Translational Liver Cancer (TLC) Consortium
    • US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet)
  • Research Groups
    • Biometry
    • Breast and Gynecologic Cancer
    • Cancer Biomarkers
    • Chemopreventive Agent Development
    • Community Oncology and Prevention Trials
    • Early Detection
    • Gastrointestinal and Other Cancers
    • Lung and Upper Aerodigestive Cancer
    • Nutritional Science
    • Prostate and Urologic Cancer
  • Clinical Trials
    • Clinical Trials Search
    • Landmark Trials
    • Clinical Trials Management
    • Why I Joined a Clinical Trial
  • Funding & Grants
    • Funding Opportunities
    • Funded Grants
    • Grantsmanship Resources
  • Resources
    • Publication Search
    • Biorepositories
    • Cancer Data Access System
  • News & Events
    • News
    • Blog
    • Meetings and Events
    • Videos and Webinars
    • Infographics
  • About DCP
    • Scientific Scope
    • Commemoration of the 50th Anniversary of the National Cancer Act
    • Director
    • DCP Leadership
    • History and Timeline
    • Historical Resources
    • Staff Directory

You are here

  1. Home
  2.   »  Research Groups
  3.   »  Lung and Upper Aerodigestive Cancer

Lung and Upper Aerodigestive Cancer

Research Groups

  • Biometry
  • Breast and Gynecologic Cancer
  • Cancer Biomarkers
  • Chemopreventive Agent Development
  • Community Oncology and Prevention Trials
  • Early Detection
  • Gastrointestinal and Other Cancers
  • Lung and Upper Aerodigestive Cancer
    • About the Lung and Upper Aerodigestive Cancer Research Group
    • Active Grants
    • Clinical Trials
    • Funding Opportunities
    • Publications
    • Staff
  • Nutritional Science
  • Prostate and Urologic Cancer

Contact the Lung and Upper Aerodigestive Cancer Research Group

Phone: 240-276-7080
Fax: 240-276-7848

For Regular Mail

Lung and Upper Aerodigestive Cancer Research Group
Division of Cancer Prevention National Cancer Institute
9609 Medical Center Drive
MSC 9781
Bethesda, ME 20892-9781

For Courier Packages

Lung and Upper Aerodigestive Cancer Research Group
Division of Cancer Prevention National Cancer Institute
9609 Medical Center Drive
Rockville, MD 20850

The Lung and Upper Aerodigestive Cancer Research Group conducts and supports research on the prevention and early detection of lung and head and neck cancers, as well as new approaches to clinical prevention studies including cancer immunoprevention.

Read more About the Lung and Upper Aerodigestive Cancer Research Group.

Staff

Funding Opportunities

Active Grants

Clinical Trials

Publications

Cancer Prevention Clinical Trials Network (CP-CTNet)

Research Centers develop and conduct early phase clinical trials to assess the preventive potential of agents and interventions of varying classes.

More about the Cancer Prevention Clinical Trials Network (CP-CTNet)

Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)

Major medical research centers conduct systematic early clinical development of promising preventive agents.

More about the Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)

Small Cell Lung Cancer (SCLC) Consortium

Six investigators conduct research to expand the understanding of the critical molecular changes in the lung that precede the development of frank SCLC and/or to identify populations at particularly high risk for SCLC.

Learn more about Small Cell Lung Cancer (SCLC) Consortium

Identifying New Biomarkers to Detect Lung Cancer Earlier

Lung cancer, the leading cause of cancer deaths worldwide killing 1.8 million people each year, is often diagnosed at an advanced stage when the chances for a cure are limited.

Follow us at:

@NCIPrevention

@NCISymptomMgmt

@NCICastle

The National Cancer Institute

Policies

DCP Home

Contact DCP

Policies

Disclaimer Policy

Accessibility

FOIA

HHS Vulnerability Disclosure

NCI's PDQ® Evidence-based Summaries

Cancer Prevention

Screening/Detection/Testing for Cancer

Supportive and Palliative Care

General Information

Cancer Prevention, Specific Cancers, Clinical Trials

Cancer Screening Topics For People Who Have No Symptoms

Managing The Side Effects of Cancer and Its Treatment

Coping With Cancer

US Preventive Services Task Force Recommendations About Cancer

NIH COVID-19 Resources

U.S. Department of Health and Human Services  |  National Institutes of Health  |  National Cancer Institute  |  USA.gov

NIH…Turning Discovery Into Health®